|
"Financial guidance: Axsome believes that its cash as of March 31, 2017 will be sufficient to fund the company's anticipated operations, based on its current operating plans, into the first quarter of 2019." http://www.nasdaq.com/press-release/axsome-therapeutics-repo… |
|
| aus der Diskussion: | AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017 |
| Autor (Datum des Eintrages): | schalkimnacken (09.05.17 13:46:33) |
| Beitrag: | 62 von 268 (ID:54899933) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |